-
Jul 29, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
Unmet Needs and Future Direction in HER2+ Breast CancerThe panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.
-
Jul 29, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBCFocusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.
-
Jul 22, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
OpinionVideoJuly 22, 2024Author(s):Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions. Video content above is prompted by the following questions:Briefly discuss the DESTINY-Breast06, including study design, primary endpoints, and safety:DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
-
Jul 22, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
OpinionVideoJuly 22, 2024Author(s):Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD. Video content above is prompted by the following questions:What has your clinical experience been monitoring for T-DXd-related interstitial lung disease (ILD)?
-
Jul 15, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
Ian Krop, MD, PhD, provides an overview of HER2-low and HER2 ultra-low breast cancer and discusses challenges encountered during diagnosis.
-
Jul 8, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
Melinda Telli, MD, provides an overview of ongoing research in HER2+ metastatic breast cancer, highlighting the DESTINY-Breast09, PATINA, INAVO122, and HER2CLIMB-05 studies.
-
Jul 8, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.
-
Jul 1, 2024 | 
onclive.com | Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
Breast cancer specialists outline their institutions’ practices regarding the choice between subcutaneous and intravenous antibody-drug conjugates in patients with HER2+ breast cancer.
-
Jul 1, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.
-
Jun 24, 2024 | 
onclive.com | Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery. Video content above is prompted by the following question(s):• Please discuss your general approach to using neoadjuvant therapy to escalate or deescalate therapy for patients?
